ArticleSurgical endoscopy2026
Transpapillary pancreatic duct stenting as a salvage therapy for refractory pancreatic fistula after distal pancreatectomy: a case series supporting the role of duodenal papilla obstruction.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsEndoscopic retrograde pancreatography (ERP) with pancreatic duct stenting is a recognized intervention for pancreatic fistulas. However, its application as a salvage therapy for refractory postoperative pancreatic fistula (POPF) after distal pancreatectomy (DP) remains less defined, particularly when guided by the hypothesis that duodenal papilla obstruction perpetuates the fistula. This study evaluated the efficacy of ERP with stenting for refractory POPF after DP and investigated the role of papilla morphology.
methodsFive patients with refractory Grade B POPF after DP were included. Refractoriness was defined as persistent high-output (> 100 mL/day) for > 3 weeks despite percutaneous drainage and medical therapy or newly developed pseudocysts. All patients underwent ERP. The key procedural goal was to traverse the papilla and place a stent into the pancreatic duct of the remnant to bypass any potential obstruction and achieve internal decompression.
resultsERP with trans-papillary stent placement was technically successful in all five patients (100%). Clinical success, defined as a dramatic reduction in fistula output (> 75%) within 72 h and complete fistula closure within 4 weeks, was achieved in all 5 patients (100%). No procedure-related complications occurred.
conclusionIn this case series, ERP with pancreatic duct stenting is a highly effective and minimally invasive salvage therapy for refractory POPF after DP. Its consistent success provides strong clinical support for the pathophysiological role of duodenal papilla obstruction. We propose that ERP should be considered early in the management algorithm for high-output POPF that fails to resolve with standard measures.
Indexed as
Identifiers
41792492What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.